Curis, Inc.
CRIS
NASDAQ·Healthcare·Biotechnology·Mkt cap $2.6M
$0.83
▼ -0.99%
P/E
—
Mkt Cap
$2.6M
52-Wk Range
$0.80–$34.80
52-Week Range
$0.80 - $34.80
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 97.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Strategic partnerships with Roche and Genentech providing development and commercialization support
- Proprietary small molecule and antibody platform technology for oncology
- Multiple clinical-stage candidates addressing high-value cancer indications
- Collaborative agreements with leading discovery firms expanding pipeline potential
Bear Case
1 risk
- High volatility (beta 3.0). Larger-than-normal price swings expected.
Growth
Revenue decline expected
Clinical trial advancement of Emavusertib in NHL and AML/MDS populations
Value
Valuation data unavailable
Momentum
Falling
-86.5% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying CRIS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 14, 2026
Reported EPS of -$4.02 vs -$5.70 consensus (+29.5% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+29.5%
Revenue trend · last 8Q
—
—
+14%
+8%
+8%
-66%
-100%
-100%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$2.9M
$3.3M
$2.4M
$2.7M
$3.2M
$1.1M
$0
$0
Margins · last 8Q
Gross
—
Profit
—
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Jul 24, 2026
vs Industry
How CRIS stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related